<DOC>
	<DOC>NCT01300143</DOC>
	<brief_summary>Indication : Hepatocellular carcinoma, maximum size 9 cm, with single or multiple nodes whose total tumor mass can technically be irradiated, non-resectable, and not a candidate for percutaneous therapy with recommended treatment via hyperselective transarterial chemoembolisation (TACE).</brief_summary>
	<brief_title>Association of Conformational High-dose Radiotherapy and of Hyperselective Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma</brief_title>
	<detailed_description>: Phase II controlled randomized trial, multicenter, comparing the benefit of additive conformational radiotherapy after therapy with hyperselective chemoembolisation (TACE) with treatment using three TACE treatments (standard of care).</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Chlorotrianisene</mesh_term>
	<criteria>Age ≥ 18 years of age ECOG 01 life expectancy ≥ 6 months Histologically proven hepatocellular carcinoma or proven according to radiological and biochemical criteria (EASLAASLD) in cirrhotic patients Maximum lesion size ≤ 9 cm Noneligible for surgery or percutaneous therapy Premature ChildPugh A or B (7 points for the ChildPugh score) AST and ALT &lt; 7 x UNL Technical possibility of conformational external radiotherapy Technical possibility of TACE All the tumor mass must be able to be treated by TACE Written consent signed by the patient Patients affiliated to a social security system Metastatic illness Minimal lesion size ≤ 5 mm Non controlled viral replication B History of radiotherapy at abdominal level Subjects capable of procreating without efficient contraception pregnancy or nursing female patient Contraindication of TACE or external conformational radiotherapy Any other concomitant experimental treatment Contraindication of Doxorubicin Patients who are unable to respect enslaving respiratory constraints if used by sites Patients who are unable to understand information and to follow protocol instructions</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>